AG-490 (Tyrphostin B42)

Name: AG-490 (Tyrphostin B42)
Brand: Selleck Chemicals
SKU: S1143
Rating: 5 (108 reviews)

For research use only.

Catalog No.S1143 Synonyms: Zinc02557947

108 publications

AG-490 (Tyrphostin B42) Chemical Structure

CAS No. 133550-30-8

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

Selleck's AG-490 (Tyrphostin B42) has been cited by 108 publications

Front Oncol, 2021, 11:650052

PubMed: 34094940 ( click the link to review the publication )

Front Nutr, 2021, 8:649640

PubMed: 33869267 ( click the link to review the publication )

Clin Exp Rheumatol, 2021, 39 Suppl 129(2):161-170

PubMed: 34014157 ( click the link to review the publication )

Oncol Rep, 2021, 10.3892/or.2021.7926

PubMed: 33432366 ( click the link to review the publication )

Int J Endocrinol, 2021, 2021:8475868

PubMed: 34335747 ( click the link to review the publication )

Clin Transl Med, 2021, 11(6):e448

PubMed: 34185428 ( click the link to review the publication )

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(18):18084-18098

PubMed: 32957082 ( click the link to review the publication )

Carcinogenesis, 2020, 41(7):993-1004

PubMed: 31740922 ( click the link to review the publication )

Oncogenesis, 2020, 10;9(2):15

PubMed: 32041943 ( click the link to review the publication )

Front Pharmacol, 2020, 26;11:273

PubMed: 32273843 ( click the link to review the publication )

J Neurodev Disord, 2020, 12(1):29

PubMed: 33172406 ( click the link to review the publication )

Food Funct, 2020, 11(5):3941-3951

PubMed: 32338270 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):632

PubMed: 32641093 ( click the link to review the publication )

Mol Cells, 2020, 43(8):749-762

PubMed: 32868491 ( click the link to review the publication )

Exp Biol Med (Maywood), 2020, 245(7):654-666

PubMed: 32075431 ( click the link to review the publication )

J Appl Toxicol, 2020, 24

PubMed: 32212198 ( click the link to review the publication )

Connect Tissue Res, 2020, 5;1-16

PubMed: 32370570 ( click the link to review the publication )

J Interferon Cytokine Res, 2020, 40(2):116-124

PubMed: 31834821 ( click the link to review the publication )

Int J Med Sci, 2020, 17(18):3174-3189

PubMed: 33173437 ( click the link to review the publication )

Pharmazie, 2020, 75(6):255-260

PubMed: 32539921 ( click the link to review the publication )

J Cancer, 2020, 11(16):4771-4782

PubMed: 32626524 ( click the link to review the publication )

Cell Prolif, 2020, 53(8):e12856

PubMed: 32648622 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:9187406

PubMed: 32832009 ( click the link to review the publication )
Anim Biotechnol, 2020, 1-13

PubMed: 32657254 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 524(4):963-969

PubMed: 32059851 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 521(2):360-367

PubMed: 31668806 ( click the link to review the publication )

Mol Med Rep, 2020, 21(1):89-96

PubMed: 31746349 ( click the link to review the publication )

J Surg Res, 2020, 248:98-108

PubMed: 31877436 ( click the link to review the publication )

Virus Res, 2020, 281:197907

PubMed: 32113834 ( click the link to review the publication )

Arch Biochem Biophys, 2020, 685:108330

PubMed: 32156533 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)E1939

PubMed: 31817171 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(17):6674-6690

PubMed: 31481647 ( click the link to review the publication )

J Cell Physiol, 2019, 234(9):15395-15406

PubMed: 30710340 ( click the link to review the publication )

J Cell Physiol, 2019, 234(11):21182-21192

PubMed: 31032948 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(9):1882-1891

PubMed: 31523190 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:57

PubMed: 30918473 ( click the link to review the publication )

Front Pharmacol, 2019, 10:620

PubMed: 31231218 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 362:59-66

PubMed: 30352208 ( click the link to review the publication )

Eur J Pharmacol, 2019, 854:289-297

PubMed: 31004602 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:9069-9076

PubMed: 31802914 ( click the link to review the publication )

Eur Rev Med Pharmacol Sci, 2019, 23(13):5840-5850

PubMed: 31298335 ( click the link to review the publication )

Oral Dis, 2019, 25(7):1769-1779

PubMed: 31365165 ( click the link to review the publication )

Can Respir J, 2019, 2019:2697376

PubMed: 31379980 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(10):2417-2429

PubMed: 29463558 ( click the link to review the publication )

J Cell Physiol, 2018, 234(1):454-463

PubMed: 29932210 ( click the link to review the publication )

Mol Carcinog, 2018, 57(3):429-439

PubMed: 29215754 ( click the link to review the publication )
Biomed Pharmacother, 2018, 101:107-114

PubMed: 29477470 ( click the link to review the publication )

Int J Oncol, 2018, 52(5):1515-1527

PubMed: 29512698 ( click the link to review the publication )

Toxicology, 2018, 408:62-69

PubMed: 29981841 ( click the link to review the publication )

Am J Transl Res, 2018, 10(2):465-473

PubMed: 29511440 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1892-1900

PubMed: 29393444 ( click the link to review the publication )

Eur J Pharmacol, 2018, 833:221-229

PubMed: 29890157 ( click the link to review the publication )

Biomed Res Int, 2018, 2018:2548378

PubMed: 30363706 ( click the link to review the publication )

Neurosci Lett, 2018, 662:219-226

PubMed: 29061394 ( click the link to review the publication )

Oncol Lett, 2018, 16(2):2517-2524

PubMed: 30013646 ( click the link to review the publication )

Int Urol Nephrol, 2018, 50(8):1535-1544

PubMed: 29508174 ( click the link to review the publication )

Antioxid Redox Signal, 2017, 27(5):251-268

PubMed: 27923278 ( click the link to review the publication )

Cardiovasc Res, 2017, 113(3):310-320

PubMed: 28158495 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 44(1):293-302

PubMed: 29132131 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(12)

PubMed: 29206176 ( click the link to review the publication )

Am J Transl Res, 2017, 9(10):4617-4626

PubMed: 29118922 ( click the link to review the publication )

Brain Res, 2017, 15;1657:202-207

PubMed: 27998796 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:2787-2799

PubMed: 29033541 ( click the link to review the publication )

Biosci Rep, 2017, 37(6)BSR20171038

PubMed: 29074558 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169665

PubMed: 28068414 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5329-5336

PubMed: 29184419 ( click the link to review the publication )

Cell Biol Int, 2017, 41(6):659-668

PubMed: 28378938 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2017, 2017:2942830

PubMed: 28630633 ( click the link to review the publication )

Oncotarget, 2017, 8(57):96958-96969

PubMed: 29228585 ( click the link to review the publication )

Oncotarget, 2017, 8(57):96993-97008

PubMed: 29228588 ( click the link to review the publication )
Oncotarget, 2017, 8(28):45848-45861

PubMed: 28507278 ( click the link to review the publication )

Oncotarget, 2017, 8(39):64853-64866

PubMed: 29029396 ( click the link to review the publication )

Oncogene, 2016,

PubMed: 26804171 ( click the link to review the publication )

PLoS Pathog, 2016, 12(4):e1005605

PubMed: 27128969 ( click the link to review the publication )

Oncoimmunology, 2016, 5(12):e1252012

PubMed: 28123894 ( click the link to review the publication )

Stem Cells Transl Med, 2016, 5(7):960-9

PubMed: 27130223 ( click the link to review the publication )

Sci Rep, 2016, 6:33676

PubMed: 27633396 ( click the link to review the publication )

Clin Exp Immunol, 2016, 184(2):147-58

PubMed: 26646950 ( click the link to review the publication )

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Exp Eye Res, 2016, 145:456-467

PubMed: 26432918 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Int J Mol Med, 2016, 38(4):1125-34

PubMed: 27599586 ( click the link to review the publication )

J Bone Miner Metab, 2016, [Epub ahead of print]

PubMed: 27628046 ( click the link to review the publication )

Scand J Immunol, 2016,

PubMed: 26482544 ( click the link to review the publication )

Mol Med Rep, 2016, 13(4):3684-90

PubMed: 26936086 ( click the link to review the publication )

J Am Soc Nephrol, 2016, 27(10):3105-3116

PubMed: 27694161 ( click the link to review the publication )

Oncotarget, 2016, 7(27):41445-41459

PubMed: 27213590 ( click the link to review the publication )

Cancer Lett, 2015, 359(2):335-43

PubMed: 25641338 ( click the link to review the publication )

Carcinogenesis, 2015, 36(1):142-50

PubMed: 25411359 ( click the link to review the publication )

Carcinogenesis, 2015, 36(1):142-50

PubMed: ( click the link to review the publication )

Neoplasia, 2015, 17(8):625-33

PubMed: 26408255 ( click the link to review the publication )

Eur Neuropsychopharmacol, 2015, 25(8):1287-99

PubMed: 25979764 ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.020

PubMed: ( click the link to review the publication )

Int J Neuropsychopharmacol, 2015, 19(2)

PubMed: 26438799 ( click the link to review the publication )
Oncol Rep, 2015, 34(4):1875-82

PubMed: 26238612 ( click the link to review the publication )

J Geriatr Cardiol, 2015, 12(6):591-9

PubMed: 26788034 ( click the link to review the publication )

Mol Cancer, 2014, 13:176

PubMed: 25047660 ( click the link to review the publication )

Carcinogenesis, 2014, 35(4):795-806

PubMed: 24265293 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4368-78

PubMed: 25312644 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2014, 307(7):C597-605

PubMed: 24944200 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7051-64

PubMed: 25216522 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(17):4697-705

PubMed: 23857601 ( click the link to review the publication )

Cancer Lett, 2013, 341(2):224-30

PubMed: 23941832 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 435(4):533-9

PubMed: 23665018 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 429(3-4):156-62

PubMed: 23142594 ( click the link to review the publication )

Prostate, 2012, 73(3):267-77

PubMed: 22821817 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Targets

JAK2 (V617F) ^[8] ()	EGFR ^[1] (Cell-free assay)
	0.1 μM

In vitro

AG-490 inhibits HER-2 driven cell proliferation with IC50 of 3.5 μM. ^[1] Corresponding to the specific dose-dependent inhibition of constitutively activated JAK2 in pre-B acute leukemia (ALL) cells, AG-490 (5 μM) almost completely blocks the growth of all ALL cells by inducing programmed cell death, with no deleterious effect on normal hematopoiesis. AG-490 does not inhibit the activities of Lck, Lyn, Btk, Syk, and Src. ^[2] AG-490 (60-100 μM) blocks the constitutive activation of Stat3sm, and inhibits spontaneous as well as interleukin 2-induced growth of mycosis fungoides (MF) tumor cells with IC50 values of 75 μM and 20 μM, respectively. ^[3] AG-490 potently inhibits IL-2-mediated human T cell growth with an IC50 of 25 μM by blocking the activities of JAK3 and STAT5a/b. ^[4] Although AG-490 alone has no effect on proliferation of FDrv210H cells at a concentration of 5 μM, AG-490 can synergize with STI571 to enhance its inhibitory effect on p210^bcr-abl driven proliferation. ^[5] AG-490 significantly inhibits the constitutive activation of Stat3 in MOPC, MPC11, and S194 cells, leading to dramatic dose-dependent apoptosis. ^[6] AG-490 (100 μM) inhibits Akt phosphorylation, inhibits the activation of nuclear factor-κB, and causes the activation of GSK-3β, leading to the reduction of c-Myc. AG-490 (50 μM) can induce apoptosis of imatinib-resistant BaF3 cells expressing T315I and E255K mutants of Bcr-Abl. ^[7] AG-490 at 30 μM inhibits not only Epo-induced phosphorylation of wild-type JAK2 but also constitutive phosphorylation of the JAK2 V617F mutant. AG-490 also potently inhibits cytokine-independent cell growth induced by the JAK2 V617F mutant in BaF3 cells. ^[8]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
BC3	MYfGeY5kfGmxbjDBd5NigQ>?	MYmxNFDjiIoEtV2=	M{fuVVI1KGh?		MXzt[YRq[XSnczDQSWwh[2WubDDhdI9xfG:\|aYO=	MXmyOlE5PDl7OR?=
BCBL1	NH[3NnVHfW6ldHnvckBCe3OjeR?=	NG\mZnQyODEkgJpCuW0>	M1jTV\|I1KGh?		NFv0VlBu\WSrYYTld{BRTUxiY3XscEBieG:ydH;zbZM>	NFfnb3QzPjF6NEm5PS=>
BC3	M2[yNWZ2dmO2aX;uJGF{e2G7	Mk\RNVAx6oDLwsXN	M4nCRlI1KGh?		NYTNNI5QdWWmaXH0[ZMh\GVvcHjvd5Bpd3K7bHH0bY9vKG:oIGPURXQ{KGOxcoLlcIF1\WRid3n0bEBJW1B5MDDhcoQhUFOIMTDy[YR2[3Srb36=	MV[yOlE5PDl7OR?=
BCBL1	M324SWZ2dmO2aX;uJGF{e2G7	NVfJOHVMOTBy4pEJxtVO	NHzaVYkzPCCq		M3PlZo1m\GmjdHXzJIRmNXCqb4PwbI9zgWyjdHnvckBw\iCVVFHUN{Bkd3K{ZXzheIVlKHerdHigTHNRPzBiYX7kJGhUTjJicnXkeYN1cW:w	NYHJWVBROjZzOES5PVk>
BC3	MnnRSpVv[3Srb36gRZN{[Xl?	NIDjdmYyODEkgJpCuW0>	NYPK[VRSOjRiaB?=		NYnGNHhUcW6mdXPld{BiKGOxbYDs[ZRmKGG3dH;wbIFocWNiZnz1fOKh	NHrwXngzPjF6NEm5PS=>
BCBL1	NUe4SYhZTnWwY4Tpc44hSXO\|YYm=	M4XMVlExOOLCidM1US=>	MnraNlQhcA>?		NULGXnRXcW6mdXPld{BiKGOxbYDs[ZRmKGG3dH;wbIFocWNiZnz1fOKh	MlywNlYyQDR7OUm=
SK-MEL-28	NV7sd5ExTnWwY4Tpc44hSXO\|YYm=	MX[1NE8yODEkgJpCuW0>	MlvmOFghcA>?	NYfxfWNWTE2VTx?=	M{m0fZJm\HWlZYOgZY5wcWurczDy[ZNqe3SjbnPl	NUXNb3c3OjV{MU[1NlI>
MeWo	MXTGeY5kfGmxbjDBd5NigQ>?	NXnwe4x3PTBxMUCw5qCKyrWP	M1PTb\|Q5KGh?	M17ENWROW09?	NHHh[Ytz\WS3Y3XzJIFvd2mtaYOgdoV{cXO2YX7j[S=>	NIGwWoYzPTJzNkWyNi=>
SK-MEL-5	MXXGeY5kfGmxbjDBd5NigQ>?	MXW1NE8yODEkgJpCuW0>	MWG0PEBp	M3Oyb2ROW09?	NHPmXoRz\WS3Y3XzJIFvd2mtaYOgdoV{cXO2YX7j[S=>	M2W1OlI2OjF4NUKy
SK-MEL-2	NGfmOHNHfW6ldHnvckBCe3OjeR?=	MWi1NE8yODEkgJpCuW0>	M3y3TlQ5KGh?	NFu1N2NFVVOR	MV\y[YR2[2W\|IHHuc4lscXNicnXzbZN1[W6lZR?=	MnzuNlUzOTZ3MkK=
B16-F0	NFnSfYtHfW6ldHnvckBCe3OjeR?=	M3nEZVUxNzFyMPMAjeK2VQ>?	NFzkSI81QCCq	M1f5WGROW09?	M{nzTpJm\HWlZYOgZY5wcWurczDy[ZNqe3SjbnPl	M4r4blI2OjF4NUKy
TRPM2/HEK	NGTqNoNHfW6ldHnvckBCe3OjeR?=	MlflNE4y6oDVMkZCpOK2VQ>?	NVjkNY9lOTYEoH3pci=>	MWXEUXNQ	NHmw[Xlz\WS3Y3XzJGgzVzJvaX7keYNm\CCFYUKrbY5kemWjc3WgbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYKsJIFv\CC2aHWgTWM2OMLidnHseYUhf2G\|IEGuO:KhyrWP	M1XaVFI2OTd7NUe0
U937	NIK5TJpHfW6ldHnvckBCe3OjeR?=	NUHmW5M3OC5z4pETNlXDqML3TR?=	MUexOeKhdWmw	M3TESWROW09?	NVT4e2g6emWmdXPld{BJOk9{LXnu[JVk\WRiQ3GyL4lv[3KnYYPlJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyMEBidmRidHjlJGlEPTEEoI\hcJVmKHejczCwMlTDqML3TR?=	M{DieVI2OTd7NUe0
TRPM2/HEK	M2rQVGZ2dmO2aX;uJGF{e2G7	MYqxNOKhyrWP	MoHZOFDDqG2rbh?=	M{LrbGROW09?	NH7ROHhz\WS3Y3XzJHRTWE1{IHHjeIl3[XSrb36g[ZZmdiCjdDDobYdpKGOxbnPlcpRz[XSrb37zJI9nKEh{T{K=	MoPoNlUyPzl3N{S=
GL37	MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MmGzNE0yOMLiwsXN	MnGxOFghcA>?		M360T5N2eHC{ZYPz[ZMhVGFiZYjwdoV{e2mxbh?=	NVL0d5Q3OjR7OUm2OVc>
NRK-52E	M2T6bWZ2dmO2aX;uJGF{e2G7	NVXrfGM{OcLiwsXN	NUnKfYRUOTBibXnu		NETTNpBjdG:la4OgeIhmKHO2aX31cIF1d3K7IHXm[oVkfCCxZjDBcochUUlib36gVIF5NTJiZYjwdoV{e2mxbtMg	M{TTZVI1PzFyNEKz
NRK-52E	M1P3fmZ2dmO2aX;uJGF{e2G7	MmrhNeKhyrWP	NFTZSWQyOCCvaX6=		MkLEZoxw[2u\|IFHu[{BKUSCrbnT1Z4VlKEOGMkSg[ZhxemW\|c3nvci=>	NEf4WZozPDdzMESyNy=>
HSC	NVLHWYhnTnWwY4Tpc44hSXO\|YYm=	MXmyNEDPxE1?	MlrPNUBp		M4rlPIFjem:pYYTld{B1cGViZHnm[oVz\W62aXHsJIVn\mWldIOgc4YhdGWydHnuJI9zKEGJRYO=	MoTKNlQ3OTRzOUm=
EJ	Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXu1NE85OCEQvF2=	MYeyOE81QC95MjDo		MmXSbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MVSyOFU5PzB2OR?=
EJ	M1;ZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\uV25TPTBxOECg{txO	NXz6TYQ3PDhiaB?=		MnfuZ4F2e2W\|IGOtdIhie2ViYYLy[ZN1	M{TC[\|I1PTh5MES5
EJ	NVvEWnF{TnWwY4Tpc44hSXO\|YYm=	Ml\TOVAwQDBizszN	Ml3POFghcA>?		MWDkc5dvemWpdXzheIV{KGNvTYnjMEBkgWOuaX7ENUwhe3W{dnn2bY4h[W6mIG\FS2Yh\XiycnXzd4lwdnN?	MXuyOFU5PzB2OR?=
HepG2	Ml7FSpVv[3Srb36gRZN{[Xl?	M2PoXlUxNTVyMDFOwG0>	NF[5PHY3OMLibXnu		M3zKSolvcGmkaYTzJJRp\SCLTD22MYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJHNVSVRzIDjUfZI4ODVrIHHu[EBUXEGWMzCoWJlzPzB3KTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M{X4UVI1OjR{MES2
SGC7901	MoTvR4VtdCCYaXHibYxqfHliQYPzZZk>	MXiwMVExOCEQvF2=	NHT3NpQzPC92OD:3NkBp		MkjuZ4F2e2W\|IHGgd4lodmmoaXPhcpQhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGSxc3Wt[IVx\W6mZX70cJkh[nW2IH7veEB1cW2nLXTldIVv\GWwdHz5	NX:ybHRCOjRzNUGyOVU>
AGS	M4LhdWNmdGxiVnnhZoltcXS7IFHzd4F6	MVmwMVExOCEQvF2=	NU\mOJFUOjRxNEivO\|IhcA>?		MUDjZZV{\XNiYTDzbYdvcW[rY3HueEBz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh\G:\|ZT3k[ZBmdmSnboTsfUBjfXRibn;0JJRqdWVvZHXw[Y5l\W62bIm=	NHHtTpUzPDF3MUK1OS=>
SGC7901	NVzLW29nTnWwY4Tpc44hSXO\|YYm=	NFXtdGw2OCEQvF2=	Mk\INlQwPDhxN{KgbC=>		MYP0bIUhdGW4ZXzzJI9nKHCMQVuyJIJm\2GwIITvJIRm[2yrbnWgZZQhOjRiaIKsJIFv\CC{ZXLveY5l\WRiYYSgO\|IhcHMEoB?=	NWHtVmxuOjRzNUGyOVU>
AGS	NWrJeI9UTnWwY4Tpc44hSXO\|YYm=	Mn\UOVAh\|ryP	M{LudlI1NzR6L{eyJIg>		NXHnTVRMfGinIHzleoVteyCxZjDwTmFMOiCkZXfhckB1dyCmZXPsbY5mKGG2IEK0JIhzNCCjbnSgdoVjd3WwZHXkJIF1KDd{IHjyxsA>	MVuyOFE2OTJ3NR?=
SGC7901	NXvYZXNUTnWwY4Tpc44hSXO\|YYm=	MUW1NEDPxE1?	M3XafFI1NzR6L{eyJIg>		NHvBR5F1cGViY4n0c5Bt[XOvaXOgcI9k[WyrenH0bY9vKG:oIIDKRWszKCiMQVuyJJBpd3OyaH;yfYxifGWmIHH0JJJme2mmdXXzJHR6ejFyMEegZY5lKFS7ckGwNFgqKGSnY4LlZZNm\CCjZoTldkBCTzR7MDD0doVifG2nboSg[o9zKDJ2IHHu[EA1QCCqcjygZpV1KHO2YYL0[YQhfG9icnXic5Vv\CCjdDC3NkBpeg>?	NEC4UpgzPDF3MUK1OS=>
AGS	MUjGeY5kfGmxbjDBd5NigQ>?	MXy1NEDPxE1?	MmDrNlQwPDhxN{KgbC=>		NV3MNHI5fGinIHP5eI9xdGG\|bXnjJIxw[2GuaYrheIlwdiCxZjDwTmFMOiBqSlHLNkBxcG:\|cHjvdplt[XSnZDDheEBz\XOrZIXld{BVgXJzMEC3JIFv\CCWeYKxNFA5MSCmZXPy[YF{\WRiYX\0[ZIhSUd2OUCgeJJm[XSvZX70JIZweiB{NDDhcoQhPDhiaIKsJIJ2fCC\|dHHyeIVlKHSxIILlZo92dmRiYYSgO\|IhcHJ?	MorGNlQyPTF{NUW=
MC3T3-E1	NXvPXFdmTnWwY4Tpc44hSXO\|YYm=	NVPOO\|NEPTBizszN	MXG0JIg>		NYnRRmZWcW6qaXLpeJMhUFOHLXnu[JVk\WRiQl3QO{BidmRiR1jSJJBzd3SnaX6g[ZhxemW\|c3nvcuKh	MXyyN\|g4Pzd\|NB?=
7TD1-DXM	NULDNZl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlS0NVAh\|ryP	MmPEO\|IhcA>?	NUTGeXpjTE2VTx?=	NG\yXJNqdmirYnn0d{Bk\WyuIHfyc5d1cA>?	MUWyN\|g4OTF3OR?=
7TD1-WD-90	NULKOVlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXFNVAh\|ryP	MYG3NkBp	Moj5SG1UVw>?	MYnpcohq[mm2czDj[YxtKGe{b4f0bC=>	NHPnTVIzOzh5MUG1PS=>
7TD1-DXM	NV3rfZY6SXCxcITvd4l{KEG\|c3H5	NFvFO5c2OCEQvF2=	MU[0PEBp	NWTTVJl[TE2VTx?=	NHqxfphqdmS3Y3XzJIFxd3C2b4Ppdy=>	MWGyN\|g4OTF3OR?=
7TD1-WD-90	MXvBdI9xfG:\|aYOgRZN{[Xl?	NF:4XVk2OCEQvF2=	MmDJOFghcA>?	M16xbmROW09?	MV\pcoR2[2W\|IHHwc5B1d3Orcx?=	NVrKPJVoOjN6N{GxOVk>
7TD1-WD-90	NX3Fc2JFTnWwY4Tpc44hSXO\|YYm=	MWW1NEDPxE1?	NV;QVmd6PiCq	M1;PPGROW09?	NG\Ud4F{cWewaX\pZ4FvfGy7IHnubIljcXS\|IITo[UBxcG:\|cHjvdplt[XSrb36gc4YhUkGNMjDhcoQheGixc4Doc5J6dGG2aX;uJI9nKFOWQWSz	MmDHNlM5PzFzNUm=
HepG2	NXjvbGRXTnWwY4Tpc44hSXO\|YYm=	MUGxNFAh\|ryP	MkHjNVIwOjRiaB?=		M1rVNYlvcGmkaYTzJHNVSVR\|IIT5do9{cW6nIIDoc5NxcG:{eXzheIlwdg>?	Mn3zNlM5OzZ2MEC=
RAW264.7	NHXG[2xHfW6ldHnvckBCe3OjeR?=	MmDvOVDDqM7:TdMg	MV:yOE81QCCq		Mo\ud5VxeHKnc4Pld{BTSU6NTD3pcoR2[2WmIH;zeIVw[2yjc4Tv[4Vv\XOrcx?=	NGTDd2EzOzZ4NUCxPC=>
RAW264.7	M4nrZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYGzU4ZCOC13MNMg{txOyqB?	M4\6NlQ5yqCq		MmSybY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:\|ZT3k[ZBmdmSnboTsfS=>	M33VbFI{PjZ3MEG4
RAW264.7	MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fnd\|AuPTEEoN88UeKh	M2LvXVQ5yqCq		M3L3dYNifXOnczDhckBienKnc4Sgc4YhWkGZMk[0Mlch[2WubIOgZZQhfGinIFewM2cyKHCqYYPlJI9nKHSqZTDj[YxtKGO7Y3zl	MWSyN\|Y3PTBzOB?=
RAW264.7	M4ixVGZ2dmO2aX;uJGF{e2G7	M4fxeFUxyqEQvF2=	NFLGcG0zPC92ODDo		NXuyb5J{cW6qaXLpeJMhWkGQS1ytbY5lfWOnZDDOSmFV[zFiZYjwdoV{e2mxbjDhcoQheGixc4Doc5J6dGG2aX;uJI9nKFOnckeyO3NVSVR\|	MkOwNlM3PjVyMUi=
A549	MmDGSpVv[3Srb36gRZN{[Xl?	MmPGNlAwPDBizszN	NUO4c29HOjBiaB?=		MknTNlAh\|ryPIFHHOFkxKHO3cIDy[ZN{\XNidHjlJJJi\GmjdHnvck1qdmS3Y3XkJIlvfmG\|aX;uJI9nKEF3NEmgZ4VtdHN?	MUmyN\|YzODF7MR?=
A549	NGLR[2RHfW6ldHnvckBCe3OjeR?=	Mm[yNVAwOjBxNECg{txO	MVGyOEBp		M2rEc5N2eHC{ZYPz[ZMhfGinIILh[IlifGmxbj3pcoR2[2WmIHXs[ZZifGmxbjDv[kBXTUeIwrC=	NV\yT2lVOjN4MkCxPVE>
HUVECs	MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MkTCNlAhyrWP	NFXKRpg1KGh?		NIP4T5NifHSnboXheIV{KEh{T{KtbY5lfWOnZDDj[YxtKHOqcnnub4Fo\SCjbnSgbY1xem:4ZXSgeIhmKGG2dHHjbI1mdnRicnH0[UBw\iC2aHWgZ4VtdHN?	M1\NelI{PDh\|OUS2
HUVECs	M1uwSWFxd3C2b4Ppd{BCe3OjeR?=	NGS0e\|AzOCEEtV2=	NWDGRmVZPCCq		NVLafoJ2e2mpbnnmbYNidnSueTDk[YNz\WG\|ZYOgeIhmKGOnbHygZZBweHSxdHnjJIlv\GW6	M4LjUFI{PDh\|OUS2
BV-2	MlPGSpVv[3Srb36gRZN{[Xl?	NYT0Nmh1OjBiwsXN	NIDzPJgyPiCq		M37URolvcGmkaYTzJGxRWy2rbnT1Z4VlKFOWQWSxJJBpd3OyaH;yfYxifGmxbjD3bZRpKGGubX;zeEBkd22ybHX0[Yx6KGSrbXnubZNp\WRiaV7PV{BmgHC{ZYPzbY9v	MYGyN\|I{PjN5MB?=
NRK-52E	M3rLN2Z2dmO2aX;uJGF{e2G7	MUS1xsDPxE1?	MWezNOKhdWmw		NGKwW4hifHSnboXheIV{KEGwZz2oNgKBmzdrLXnubIljcXSnZDDUS2Yu\|rJzIH3SUmEh[XRiMUdCpIjDqA>?	NH3JNXQzOzF5NEe1Oy=>
SW620	NXXicpY2TnWwY4Tpc44hSXO\|YYm=	NFjyfIMzOCEEtV2=	NHrWVo4yNzZiaB?=		NEj2fJdqdmirYnn0d{BxNVOWQWSzJIFkfGm4YYTpc44>	MXSyN\|EyODZ{NR?=
RPE	M17VeWZ2dmO2aX;uJGF{e2G7	MoG3N\|AhyrWPwrC=	Mlz4N{Bp		NIflcWdqdmirYnn0d{B1cGViaX7keYN1cW:wIH;mJJAuW1SDVEOg[ZhxemW\|c3nvci=>	MVqyN\|A6PDB4Nx?=
SW1116	MXTGeY5kfGmxbjDBd5NigQ>?	M3f6O\|ExOCEEtV5CpC=>	MWeyOE81QC95MjDo		NGfMNIdl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhUkGNMjDhcoQheEqDS{KgeIlu\S2mZYDlcoRmdnSueR?=	NWTn[2p1OjJyNUC3PVA>
HT29	MVjGeY5kfGmxbjDBd5NigQ>?	MV2xNFAhyrWPwrC=	M4P2Z\|I1NzR6L{eyJIg>		MUHk[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gTmFMOiCjbnSgdGpCUzJidHnt[U1l\XCnbnTlcpRtgQ>?	NX60VXRJOjJyNUC3PVA>
SW1116	NFfOR2xHfW6ldHnvckBCe3OjeR?=	MkP3NVAxKML3TdMg	NX\mbYVOOjRxNEivO\|IhcA>?		MVjk[YNz\WG\|ZYOgeIhmKHCVVFHUN{Bt\X[nbIOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYNCpC=>	NEPZTnUzOjB3MEe5NC=>
HT29	M33WXmZ2dmO2aX;uJGF{e2G7	NIe0NGQyODBiwsXNxsA>	Mo\5NlQwPDhxN{KgbC=>		MnLx[IVkemWjc3XzJJRp\SCyU2TBWFMhdGW4ZXzzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXyxsA>	M3\LOVIzODVyN{mw
ARPE-19	NVKwd\|htTnWwY4Tpc44hSXO\|YYm=	NEm2[ZY2yqEQvF2=	NW\wcWhPOzEEoH3pci=>		M2\kXIlvcGmkaYTzJGpCUzJicHjvd5Bpd3KrbHH0bY9v	MWGyNVYzODl4Mx?=
HSC-T6	M{HIcmFxd3C2b4Ppd{BCe3OjeR?=	M3rZeVExyqEQvF2=	MX6yxsBpyqB?		NFLFNFlqdmirYnn0d{B1cGViYYDvdJRwe2m\|IH;mJGhUSy2WNjDj[YxteyCrbnT1Z4VlKGK7IFPESS=>	MYGyNVM6Pjl7OB?=
HSC-T6	NX3IOmk2TnWwY4Tpc44hSXO\|YYm=	NXrDOYtyOTEEoN88US=>	NFj0fJQzyqCqwrC=		MUXpcohq[mm2czD0bIUh\XiycnXzd4lwdnNib3[gdHkuW1SDVEGgZY5lKEKjZDDpcoR2[2WmIHL5JGNFTQ>?	M3XyNVIyOzl4OUm4
Hep-2	NV71XXoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXGO5gzPS1zMECg{txO	NI\wPVYzPC92OD:3NkBp		M2HjZolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	M17ZTVIyOzB7NEix
Hep-2	Mo\MRZBweHSxc3nzJGF{e2G7	MUW1NEDPxE1?	NX;yO\|NzOjRxNEivO\|IhcA>?		MX3pcoR2[2W\|IHPlcIwh[XCxcITvd4l{KHSrbXWg[IVx\W6mZX70cJk>	NVz2PFNsOjF\|MEm0PFE>
Hep-2	MUfGeY5kfGmxbjDBd5NigQ>?	MoTkOVAh\|ryP	NGLqbnQzPC92OD:3NkBp		NGXYOIJqdmirYnn0d{BIOSC2bzDTJINmdGxiY4njcIUhfHKjboPpeIlwdiCjbnSgbY5lfWOnczDHNUBk\WyuIHP5Z4xmKGG{cnXzeC=>	MUOyNVMxQTR6MR?=
Hep-2	Mkn4SpVv[3Srb36gRZN{[Xl?	NXWwPVBkPTBizszN	NILu[mQzPC92OD:3NkBp		NF[4dJlld3ewcnXneYxifGW\|IITo[UBUXEGWMzygdE1UXEGWMzDhcoQhe3W{dnn2bY4heHKxdHXpckBt\X[nbIO=	NULBPFdVOjF\|MEm0PFE>
KF8	NEPBcFlHfW6ldHnvckBCe3OjeR?=	M{\sXVExyqEQvF5CpC=>	NUXmcmRYOcLiaB?=	NGPqb4xFVVORwrC=	MUfpcohq[mm2czDJUE0{Oy2rbnT1Z4VlKE6ILd86RkBi[3SrdnH0bY9v	NHH0ZnMzODl2MEC0OS=>
KF8	NFnzcHVHfW6ldHnvckBCe3OjeR?=	NWPTZpVnOTEEoN88UeKh	NGrH[pIyyqCqwrC=	Mn:0SG1UV8Li	M1PvfIlvcGmkaYTzJGlNNTN\|LXnu[JVk\WRiSd86Ru6yKGSnZ4Lh[IF1cW:wIHHu[EBPTi4QulKgZYN1cX[jdHnvci=>	MW[yNFk1ODB2NR?=
HEL	NWS3N5BQTnWwY4Tpc44hSXO\|YYm=	MVexNFDDqM7:TR?=	NGrVR3kyOi15MjDo		NUftdGZicW6qaXLpeJMhfGinIHzleoVtKG:oIICtTmFMOixiSlHLNi=>	MXKyNFYzOTB4MR?=
HEL	Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljaNVAxyqEQvF2=	NYXUbIdVOC13IHS=		NHqwOHZz\WS3Y3XzJIdzd3e2aDDv[kBLSUt{Vk[xO2Yu\XiycnXzd4lv\yCKRVygZ4VtdHN?	M2jMdVIxPjJzME[x
A-172	NY\NZ5NuTnWwY4Tpc44hSXO\|YYm=	NVzSO3RYPTBxMUCwxsDPxE1?	NHLZTo81QCCq		NUHpW2VOemWmdXPld{B1cGVibHX2[Yx{KG:oIHPvcpN1cXS3dHn2[Yx6KGGldHn2ZZRm\CCVVFHUN{BqdiCjIITpcYUu\GWyZX7k[Y51KGGwZDDkc5NmNWSncHXu[IVvfCCoYYPobY9v	MYSyNFU5QTV{NR?=
MZ-18	MW\GeY5kfGmxbjDBd5NigQ>?	NV;EZ4ZMPTBxMUCwxsDPxE1?	MV[0PEBp		MlmxdoVlfWOnczD0bIUhdGW4ZXzzJI9nKGOxboP0bZR2fGm4ZXz5JIFkfGm4YYTl[EBUXEGWMzDpckBiKHSrbXWt[IVx\W6mZX70JIFv\CCmb4PlMYRmeGWwZHXueEBn[XOqaX;u	M{TKUFIxPTh7NUK1
MZ-54	NV;NSIhNTnWwY4Tpc44hSXO\|YYm=	NH7RVmI2OC9zMEFCpO69VQ>?	M1XEW\|Q5KGh?		M3fqWpJm\HWlZYOgeIhmKGyndnXsd{Bw\iClb37zeIl1fXSrdnXsfUBi[3SrdnH0[YQhW1SDVEOgbY4h[SC2aX3lMYRmeGWwZHXueEBidmRiZH;z[U1l\XCnbnTlcpQh\mG\|aHnvci=>	NEK1PJAzODV6OUWyOS=>
MZ-256	M{Lsd2Z2dmO2aX;uJGF{e2G7	MmLMOVAwOTBywrFOwG0>	M{nIV\|Q5KGh?		NHHlWXJz\WS3Y3XzJJRp\SCuZY\lcJMhd2ZiY3;ud5RqfHW2aY\lcJkh[WO2aY\heIVlKFOWQWSzJIlvKGFidHnt[U1l\XCnbnTlcpQh[W6mIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44>	NESxUJczODV6OUWyOS=>
MZ-304	NVfrdoxnTnWwY4Tpc44hSXO\|YYm=	MXW1NE8yODEEoN88US=>	MYO0PEBp		MofodoVlfWOnczD0bIUhdGW4ZXzzJI9nKGOxboP0bZR2fGm4ZXz5JIFkfGm4YYTl[EBUXEGWMzDpckBiKHSrbXWt[IVx\W6mZX70JIFv\CCmb4PlMYRmeGWwZHXueEBn[XOqaX;u	NGLIO3MzODV6OUWyOS=>
A-172	NHS5OoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYW1NE8yODEEoN88US=>	MYK0PEBp		M3;oe4xm[WS\|IITvJIEhe3SjdHnzeIlk[WyueTDzbYdvcW[rY3HueEBz\WS3Y4Tpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIH;2[ZIh[SC2aX3lJJBmemmxZDDv[kA1QMLiaB?=	M2O4N\|IxPTh7NUK1
MZ-18	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3ftbVUxNzFyMNMg{txO	M4HkOFQ5KGh?		MXzs[YFleyC2bzDhJJN1[XSrc4TpZ4FtdHlic3nncolncWOjboSgdoVlfWO2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCxdnXyJIEhfGmvZTDw[ZJqd2Rib3[gOFjDqGh?	NGLlNYwzODV6OUWyOS=>
MZ-54	NIqyd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInCTGw2OC9zMEFCpO69VQ>?	NVTjdXhOPDhiaB?=		MVjs[YFleyC2bzDhJJN1[XSrc4TpZ4FtdHlic3nncolncWOjboSgdoVlfWO2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCxdnXyJIEhfGmvZTDw[ZJqd2Rib3[gOFjDqGh?	M4DpfFIxPTh7NUK1
MZ-256	NGHBfHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;nW3RRPTBxMUCwxsDPxE1?	MkHOOFghcA>?		M4HHWIxm[WS\|IITvJIEhe3SjdHnzeIlk[WyueTDzbYdvcW[rY3HueEBz\WS3Y4Tpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIH;2[ZIh[SC2aX3lJJBmemmxZDDv[kA1QMLiaB?=	MUGyNFU5QTV{NR?=
MZ-304	NFO3bm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HXfVUxNzFyMNMg{txO	MX[0PEBp		NYrGdmVTdGWjZIOgeI8h[SC\|dHH0bZN1cWOjbHz5JJNq\26rZnnjZY51KHKnZIXjeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gc5ZmeiCjIITpcYUheGW{aX;kJI9nKDR6wrDo	NXO5O2pFOjB3OEm1NlU>
A-172	M33C[2Z2dmO2aX;uJGF{e2G7	M{ntTlUxNzFyMNMg{txO	MoHQOFghcA>?		NWPzdHIycW6qaXLpeJMhdWmpcnH0bY9v	NYLFdYVUOjB3OEm1NlU>
MZ-18	M1LSUGZ2dmO2aX;uJGF{e2G7	NFrB[2M2OC9zMEFCpO69VQ>?	M{fzR\|Q5KGh?		MkD4bY5pcWKrdIOgcYloemG2aX;u	NVX1R4ZDOjB3OEm1NlU>
MZ-54	NUXibGQ6TnWwY4Tpc44hSXO\|YYm=	NGfRVpg2OC9zMEFCpO69VQ>?	MVi0PEBp		MWXpcohq[mm2czDtbYdz[XSrb36=	M37jV\|IxPTh7NUK1
MZ-256	M2XHT2Z2dmO2aX;uJGF{e2G7	MlrzOVAwOTBywrFOwG0>	NGL2SHE1QCCq		NXLVfGdkcW6qaXLpeJMhdWmpcnH0bY9v	NHzzNmMzODV6OUWyOS=>
MZ-304	NEXiPYRHfW6ldHnvckBCe3OjeR?=	M{eyfFUxNzFyMNMg{txO	M1nVSlQ5KGh?		M3;q[olvcGmkaYTzJI1q\3KjdHnvci=>	MoLONlA2QDl3MkW=
A-172	NEPLT25HfW6ldHnvckBCe3OjeR?=	MXOxNFDDqM7:TR?=	MVO0PEBp		MknXbY5pcWKrdIOgbY53[XOrb36=	MmLvNlA2QDl3MkW=
MZ-18	Ml35SpVv[3Srb36gRZN{[Xl?	MmCwNVAxyqEQvF2=	Ml;OOFghcA>?		MnPsbY5pcWKrdIOgbY53[XOrb36=	MlTqNlA2QDl3MkW=
MZ-54	M1Hnb2Z2dmO2aX;uJGF{e2G7	M3XRPVExOMLizszN	NH\UcG41QCCq		NEe1XW5qdmirYnn0d{Bqdn[jc3nvci=>	MWeyNFU5QTV{NR?=
MZ-256	NHXDSohHfW6ldHnvckBCe3OjeR?=	MVGxNFDDqM7:TR?=	MYS0PEBp		MojCbY5pcWKrdIOgbY53[XOrb36=	NG\IcmgzODV6OUWyOS=>
MZ-304	NVuwRVd{TnWwY4Tpc44hSXO\|YYm=	M2T4e\|ExOMLizszN	M365WFQ5KGh?		NHzHWGFqdmirYnn0d{Bqdn[jc3nvci=>	MVqyNFU5QTV{NR?=
A-172	NXrqXWd[TnWwY4Tpc44hSXO\|YYm=	MmnLOVAwOTBywrFOwG0>	M3\a[FQ5KGh?		NHLPdWFz\WS3Y3XzJJRz[W6\|Y4LpdJRqd25ib3[gUW1RKGenbnXzJIFv\CC{ZXT1Z4V{KGWweontZZRq[yCjY4Tpeol1gSCxZjDNUXB{	M{\ZUlIxPTh7NUK1
MZ-18	MWDGeY5kfGmxbjDBd5NigQ>?	MkW2OVAwOTBywrFOwG0>	NVX3fG13PDhiaB?=		NEGyfnZz\WS3Y3XzJJRz[W6\|Y4LpdJRqd25ib3[gUW1RKGenbnXzJIFv\CC{ZXT1Z4V{KGWweontZZRq[yCjY4Tpeol1gSCxZjDNUXB{	MXiyNFU5QTV{NR?=
MZ-54	NF;UZ2FHfW6ldHnvckBCe3OjeR?=	M4LSflUxNzFyMNMg{txO	NYLrS\|JLPDhiaB?=		MWLy[YR2[2W\|IITyZY5{[3KrcITpc44hd2ZiTV3QJIdmdmW\|IHHu[EBz\WS3Y3XzJIVvgnmvYYTpZ{Bi[3Srdnn0fUBw\iCPTWDz	NVPlUmFFOjB3OEm1NlU>
MZ-256	NGraW\|BHfW6ldHnvckBCe3OjeR?=	M3O5[lUxNzFyMNMg{txO	NVjUeYN1PDhiaB?=		MYXy[YR2[2W\|IITyZY5{[3KrcITpc44hd2ZiTV3QJIdmdmW\|IHHu[EBz\WS3Y3XzJIVvgnmvYYTpZ{Bi[3Srdnn0fUBw\iCPTWDz	MXGyNFU5QTV{NR?=
MZ-304	MWDGeY5kfGmxbjDBd5NigQ>?	MlviOVAwOTBywrFOwG0>	M{XQd\|Q5KGh?		MXvy[YR2[2W\|IITyZY5{[3KrcITpc44hd2ZiTV3QJIdmdmW\|IHHu[EBz\WS3Y3XzJIVvgnmvYYTpZ{Bi[3Srdnn0fUBw\iCPTWDz	M{PhRVIxPTh7NUK1
SW1990	NH\6XGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVi2O2MyOjBizszN	NXfSV\|M2OjRxNEivO\|IhcA>?		MoW1bY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=>	MoKxNlA1QDJ6NUi=
SW1990	MUnGeY5kfGmxbjDBd5NigQ>?	NIrjSo8zOCEQvF2=	NULrUVJ4OjRiaB?=		Mnnh[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG1OWC1{IHHu[EBXTUeIIH3SUmF{	Mn7hNlA1QDJ6NUi=
SW1990	M2rQTWZ2dmO2aX;uJGF{e2G7	NIPubJEzOCEQvF2=	M4X5cFI1KGh?		Mnu2[IVkemWjc3XzJJRp\SCrboTlcpNqfHlib3[gdE1UfGG2MzDlfJBz\XO\|aX;u	MknQNlA1QDJ6NUi=
SW1990	NEXqTJRKdn[jc3nvckBCe3OjeR?=	NVexSXUzOjBizszN	NWHyS5V{OjRiaB?=		M4Dmc5Jm\HWlZYOgbY53[XOrb36gc4YhW1dzOUmwJINmdGy\|wrC=	NHnve4czODR6Mki1PC=>
THP1	NF:3R\|dHfW6ldHnvckBCe3OjeR?=	MXixNEB2VQ>?	MkfkN\|AhdWmwwrC=		MXrpcohq[mm2czDTWGFVOyC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44h[nlib4\ldkA3OCV?	NF:4dIczODN7M{[5NC=>
BMMC	MkKySpVv[3Srb36gRZN{[Xl?	Ml\INE0yOCEQvF2=	MXyxOeKhdWmw		NWnMTlJ3cW6qaXLpeJMhVFSFNNMgdoVt\WG\|ZTDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36ge4l1cCCwZXHyJINwdXCuZYTlJIlvcGmkaYTpc44h[XRiY3;uZ4VvfHKjdHnvcpMh6qn-MUFCpO69VQ>?	MYKxPVg{PTh2NR?=
A549	NWq1bHM{TnWwY4Tpc44hSXO\|YYm=	MmL3NVUh\|ryv	NWjNWoJoOSCq		M4jSbYlvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiU2TBWFEhd25idInyc5NqdmViN{CxJJdieyCmZYTlZ5Rm\CBzNTDtbY4h[W[2ZYKgV3BGKEJidILlZZRu\W62	NXrSRnE1OTl6MEG2OlU>
OVCAR-3	M{jlXmZ2dmO2aX;uJGF{e2G7	MkPhNVAhfU1?	NGPwVXgyKGh?		NIK4NYVqdmirYnn0d{BNWEFvaX7keYNm\CCVVFHUN{BxcG:\|cHjvdplt[XSrb36=	MWGxPVY1PzN4Mx?=
PA-1	NYD4O4lKTnWwY4Tpc44hSXO\|YYm=	NGDlO\|kyOCC3TR?=	NVq2S4dyOSCq		NGjCVVJqdmirYnn0d{BNWEFvaX7keYNm\CCVVFHUN{BxcG:\|cHjvdplt[XSrb36=	MmDqNVk3PDd\|NkO=
OVCAR-3	MWPGeY5kfGmxbjDBd5NigQ>?	MX[xNEB2VQ>?	M1X4cVEhcA>?		MWTpcohq[mm2czCgUHBCNWmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCvb4TpcIl1gQ>?	M3;Hb\|E6PjR5M{[z
PA-1	Mm[wSpVv[3Srb36gRZN{[Xl?	MoHsNVAhfU1?	MUOxJIg>		NWntSJBrcW6qaXLpeJMhKEySQT3pcoR2[2WmIH;2ZZJq[W5iY3HuZ4VzKGOnbHygcY91cWyrdIm=	Mn3mNVk3PDd\|NkO=
Jurkat	M3PNRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHQOVAh\|ryP	MYKyOE81QC95MjDo		NYLE[mVF\W6qYX7j[ZMhXFKDSVytbY5lfWOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9v	MlriNVk2PjR6OUG=
SUPT1	NFTwXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUW1NEDPxE1?	M1f0O\|I1NzR6L{eyJIg>		NWK4TIFt\W6qYX7j[ZMhXFKDSVytbY5lfWOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9v	MmThNVk2PjR6OUG=
Jurkat	NH7Je2JCeG:ydH;zbZMhSXO\|YYm=	NF3XZ4k2OCEQvF2=	NXf3V4lbOjRxNEigbC=>		NEHtdZVmdmijbnPld{BVWkGLTD3pcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NIPGfXkyQTV4NEi5NS=>
SUPT1	NH;YTW9CeG:ydH;zbZMhSXO\|YYm=	M{T6e\|UxKM7:TR?=	Mon5NlQwPDhiaB?=		Ml\C[Y5p[W6lZYOgWHJCUUxvaX7keYNmeyClZXzsJIFxd3C2b4Ppdy=>	MmX4NVk2PjR6OUG=

... Click to View More Cell Line Experimental Data

In vivo

Administration of AG-490 drastically reduces the numbers of CD45⁺ and HLA-DR⁺ cells from 48 % and 46% in bone marrow of untreated mice, as well as 38% and 22% in the spleen of untreated mice to undetectale levels. ^[2] In vivo administration of AG-490 causes murine myeloma tumor cell apoptosis but does not inhibit IL-12-mediated macrophage activation and IFN-γ production by lymphocytes. ^[6] Consistent with the in vitro blocking of JAK2 V617F mutant activity, AG-490 treatment at 0.5 mg/day for 10 days effectively inhibits JAK2 V617F mutant-induced tumorigenesis and tumor cell invasion in nude mice. ^[8] Combined therapy with AG-490 and IL-12 induces greater antitumor effects than either agent alone in a murine myeloma tumor model. ^[6]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase autophosphorylation: AG-490 is dissolved in DMSO 10%-H₂O-ethanol 45%. Crude membrane extracts (0.125 μg/mL) are preactivated with EGF (20 nM) in 50 mM HEPES buffer, pH 7.6, and 125 mM NaCl, for 15 minutes at 4 °C. Autophosphorylation activity of EGFR or ErbB2 kinase is assayed at 4 °C for 30 seconds in V-shaped 96-well plates. Membrane extracts (8 μL) are added to each well containing reaction mixture (12 μL, 50mM, HEPES, pH 7.4,125 mM NaCl, 12 mM M₈Ac₂, 2 mM MnCl₂, 1 mM NaVO₃, 1 μM ATP, and 1 μCi[γ-³²P]ATP, final concentrations) and increasing concentrations of AG-490 (4 μL). After termination by addition of hot sample buffer, the samples are run on a 6% SDS-polyacrylamide gel electrophoresis minigel, the gels dried, and autoradiography performed during the linear exposure time period. The receptor bands are scanned densitrometrically, and the results analyzed by the Ez-Fit program. For the analysis of autophosphorylation of JAK2, JAK2 is immunoprecipitated by using anti-JAK2 antibody from lysates of G2 cells pretreated for 16 hours with increasing concentrations of AG-490 (0-50 μM). Immune complexes are then immunoblotted with anti-phosphotyrosine antibody. A dose-dependent inhibition of in vitro kinase activity is demonstrated by assessing JAK2 autophosphorylation.
Cell Research: ^[2]	- Collapse Cell lines: Pre-B ALL Concentrations: Dissolved in DMSO, final concentrations ~ 50 μM Incubation Time: 16 hours Method: Cells are exposed to different concentrations of AG-490 for 16 hours. For the determination of cell proliferation, [³H]tymidine (1 μCi) is added 6 hours or more before the cultures are terminated. Cells are then collected and samples counted in a liquid scintillation counter. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: SCID mice intravenously injected with ALL cells Dosages: 0.85 mg + 0.5 mg daily Administration: Continuous pump infusion supplemented with daily intraperitoneal injections (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	58 mg/mL (197.07 mM)
	Water	Insoluble
	Ethanol	'6 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG300+5% Tween80+50% ddH2O For best results, use promptly after mixing.	6.25 mg/ml

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AG-490 (Tyrphostin B42) SDF

Molecular Weight	294.30
Formula	C₁₇H₁₄N₂O₃
CAS No.	133550-30-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Zinc02557947
Smiles	C1=CC=C(C=C1)CNC(=O)C(=CC2=CC(=C(C=C2)O)O)C#N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to know whether AG490 (S1143) goes to CNS through BBB, or not?
Answer:
AG-490 can go through the BBB. You can see this reference: http://bloodjournal.hematologylibrary.org/content/111/4/2062.full.html.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Selective EGFR Inhibitor

Erlotinib HCl (OSI-744) : EGFR-selective, IC50=2 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related EGFR Products

Erlotinib (OSI-774) ^New

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib (GW-572016)

Lapatinib (GW-572016, GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

Choose Your Country or Region

By Signaling Pathways

By product type

AG-490 (Tyrphostin B42)